Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daryl Geers

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Science Immunology|February 3, 2022
Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipientsCorine H GeurtsvanKessel, Daryl Geers, Katharina S Schmitz, et al.
Science Immunology|May 26, 2021
SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccineesDaryl Geers, Marc C Shamier, Susanne Bogers, et al.
Iscience|December 12, 2022
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccinationDaryl Geers, Roos S G Sablerolles, Debbie van Baarle, et al.
The Lancet. Infectious Diseases|November 10, 2022
Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trialMarcia M L Kho, A Lianne Messchendorp, Sophie C Frölke, et al.
Nature Communications|May 18, 2024
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boostersLuca M Zaeck, Ngoc H Tan, Wim J R Rietdijk, et al.
Transplantation|November 10, 2021
The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney TransplantJan-Stephan F Sanders, Frederike J Bemelman, A Lianne Messchendorp, et al.
The Lancet. Infectious Diseases|April 23, 2023
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trialNgoc H Tan, Daryl Geers, Roos S G Sablerolles, et al.
The Journal of Infection|January 10, 2026
Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccinationDaryl Geers, Muriel Aguilar-Bretones, Luca M Zaeck, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 15, 2025
Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled TrialA Lianne Messchendorp, Luca M Zaeck, Pim Bouwmans, et al.
The Journal of Infectious Diseases|November 19, 2022
Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary VaccinationMarlou J Jongkees, Daryl Geers, Kathryn S Hensley, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Science Immunology|February 3, 2022
Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipientsCorine H GeurtsvanKessel, Daryl Geers, Katharina S Schmitz, et al.
Science Immunology|May 26, 2021
SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccineesDaryl Geers, Marc C Shamier, Susanne Bogers, et al.
Iscience|December 12, 2022
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccinationDaryl Geers, Roos S G Sablerolles, Debbie van Baarle, et al.
The Lancet. Infectious Diseases|November 10, 2022
Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trialMarcia M L Kho, A Lianne Messchendorp, Sophie C Frölke, et al.
Nature Communications|May 18, 2024
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boostersLuca M Zaeck, Ngoc H Tan, Wim J R Rietdijk, et al.
Transplantation|November 10, 2021
The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney TransplantJan-Stephan F Sanders, Frederike J Bemelman, A Lianne Messchendorp, et al.
The Lancet. Infectious Diseases|April 23, 2023
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trialNgoc H Tan, Daryl Geers, Roos S G Sablerolles, et al.
The Journal of Infection|January 10, 2026
Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccinationDaryl Geers, Muriel Aguilar-Bretones, Luca M Zaeck, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 15, 2025
Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled TrialA Lianne Messchendorp, Luca M Zaeck, Pim Bouwmans, et al.
The Journal of Infectious Diseases|November 19, 2022
Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary VaccinationMarlou J Jongkees, Daryl Geers, Kathryn S Hensley, et al.
Pageof 4